{"id":"W3167136803","doi":"10.1016/j.cgh.2021.06.011","title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study","year":2021,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Research and Development; University of California, San Francisco; Genentech; Ferring Pharmaceuticals; UCB; Biogen; National Institute of Diabetes and Digestive and Kidney Diseases; Seres Therapeutics; Hospira; Johns Hopkins University; Boehringer Ingelheim; Janssen Pharmaceuticals; CMC Microsystems; Gilead Sciences; AbbVie; Abbott Laboratories; Merck; Crohn's and Colitis Foundation of America; AstraZeneca; Pfizer","keywords":"Medicine; Ulcerative colitis; Internal medicine; Gastroenterology; Inflammatory bowel disease; Calprotectin; Adverse effect; Population; Tolerability; Immunology; Disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001619706,0.001546065,0.002632284,0.0004812222,0.0004677641,0.00111921,0.0008348198,0.001743041,0.005347789],"category_scores_gemma":[0.0007951542,0.0005884332,0.0020655,0.0003908264,0.001009487,0.0009959015,0.0002927118,0.003257128,0.001337647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007394141,"about_ca_system_score_gemma":0.001166802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005880035,"about_ca_topic_score_gemma":0.001508375,"domain_scores_codex":[0.9995448,0.0001885251,0.00002120483,0.000067614,0.00004989282,0.0001278992],"domain_scores_gemma":[0.9993033,0.0001228672,0.0001531167,0.00006892197,0.00004370906,0.0003081116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8082091,0.03824175,0.002958972,0.0009867112,0.002212944,0.0001811813,0.0001625697,0.002027129,0.03470825,0.000295099,0.004046446,0.1059698],"study_design_scores_gemma":[0.5157317,0.4675541,0.009285418,0.0000513014,0.0008710548,0.0002273471,0.00004718878,0.001036991,0.002692051,0.0002422087,0.002221323,0.00003937791],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902964,0.003697437,0.0008032469,0.0005156278,0.0001644853,0.001348642,0.001109085,0.0001968521,0.001868142],"genre_scores_gemma":[0.9876899,0.002376478,0.001415928,0.001127896,0.0002612433,0.001515081,0.001781452,0.00004285869,0.003789129],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005347789,"threshold_uncertainty_score":0.01789016,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02881228585038049,"score_gpt":0.3652693861898719,"score_spread":0.3364571003394914,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}